PCI Biotech Holding ASA Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-16.42	-20.32	-55.1	-88.39	-72.24	Upgrade
Depreciation & Amortization	0.3	0.37	0.63	2.54	2.21	Upgrade
Asset Writedown & Restructuring Costs	-	-	5.77	-	-	Upgrade
Stock-Based Compensation	0.83	1.96	-1.29	12.94	6.34	Upgrade
Other Operating Activities	0.06	0.05	-0.12	2.57	-8.45	Upgrade
Change in Accounts Receivable	-1.27	3.59	6.04	0.96	1.48	Upgrade
Change in Accounts Payable	1.01	0.22	-3.25	-1.45	-3.41	Upgrade
Change in Other Net Operating Assets	1.73	-0.84	-11.73	2.52	-3.32	Upgrade
Operating Cash Flow	-13.76	-14.97	-59.04	-68.31	-77.39	Upgrade
Capital Expenditures	-	-	-	-0.34	-3.92	Upgrade
Investing Cash Flow	-	-	-	-0.34	-3.92	Upgrade
Long-Term Debt Repaid	-0.36	-0.44	-0.68	-0.67	-0.67	Upgrade
Net Debt Issued (Repaid)	-0.36	-0.44	-0.68	-0.67	-0.67	Upgrade
Issuance of Common Stock	-	-	-	-	0.32	Upgrade
Financing Cash Flow	-0.36	-0.44	-0.68	-0.67	-0.35	Upgrade
Foreign Exchange Rate Adjustments	-	-	0.2	-2.53	8.53	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	0	-	Upgrade
Net Cash Flow	-14.12	-15.41	-59.52	-71.85	-73.14	Upgrade
Free Cash Flow	-13.76	-14.97	-59.04	-68.65	-81.31	Upgrade
Free Cash Flow Margin	-204.28%	-500.67%	-1242.99%	-1094.34%	-1103.56%	Upgrade
Free Cash Flow Per Share	-0.37	-0.40	-1.58	-1.84	-2.18	Upgrade
Cash Interest Paid	-	0	0.05	0.2	-	Upgrade
Levered Free Cash Flow	-8.62	-9.12	-44.95	-36.62	-50.26	Upgrade
Unlevered Free Cash Flow	-8.58	-9.02	-44.87	-36.56	-50.01	Upgrade
Change in Net Working Capital	-1.51	-2.55	8.93	-2.07	3.31	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.